List of Advaxis patents | 6 results

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10900044 Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof	Patent 10900044 was granted and assigned to Advaxis on January, 2021 by the United States Patent and Trademark Office.	Advaxis	Advaxis	United States Patent and Trademark Office	10900044	January 26, 2021
‌ US Patent 10258679 Recombinant	Patent 10258679 was granted and assigned to Advaxis on April, 2019 by the United States Patent and Trademark Office.	Advaxis	Advaxis	United States Patent and Trademark Office	10258679	April 16, 2019
‌ US Patent 10058599 Suppressor cell function inhibition following	Patent 10058599 was granted and assigned to Advaxis on August, 2018 by the United States Patent and Trademark Office.	Advaxis	Advaxis	United States Patent and Trademark Office	10058599	August 28, 2018
‌ US Patent 10143734 Biomarker directed multi-target immunotherapy	Patent 10143734 was granted and assigned to Advaxis on December, 2018 by the United States Patent and Trademark Office.	Advaxis	Advaxis	United States Patent and Trademark Office	10143734	December 4, 2018
‌ US Patent 11179339 Compositions and methods for lyophilization of bacteria or listeria strains	Patent 11179339 was granted and assigned to Advaxis on November, 2021 by the United States Patent and Trademark Office.		Advaxis	United States Patent and Trademark Office	11179339	November 23, 2021
‌ US Patent 11702664 Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof		Advaxis	Advaxis	United States Patent and Trademark Office	11702664	July 18, 2023